Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients

Nicholas G. Gottardo; Amar Gajjar

doi:10.1158/1078-0432.CCR-23-2331

Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients

Nicholas G. Gottardo, Amar Gajjar

Paediatrics

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression-free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4 Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients (n ¼ 3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.

Original language	English
Pages (from-to)	4996-4998
Number of pages	3
Journal	Clinical Cancer Research
Volume	29
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-2331
Publication status	Published - 15 Dec 2023

Access to Document

10.1158/1078-0432.CCR-23-2331Licence: CC BY-NC-ND

Cite this

@article{3f4cb97a54cf420ab6513ac94daa0003,

title = "Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients",

abstract = "Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression-free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4 Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients (n ¼ 3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.",

author = "Gottardo, {Nicholas G.} and Amar Gajjar",

note = "Funding Information: This work was supported by Stan Perron Charitable Foundation (Stan Perron Charitable Trust; to N.G. Gottardo) and American Lebanese Syrian Associated Charities (ALSAC; to A. Gajjar). Publisher Copyright: c2023 The Authors; Published by the American Association for Cancer Research.",

year = "2023",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-23-2331",

language = "English",

volume = "29",

pages = "4996--4998",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

TY - JOUR

T1 - Verschlimmbesserung

T2 - Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients

AU - Gottardo, Nicholas G.

AU - Gajjar, Amar

N1 - Funding Information: This work was supported by Stan Perron Charitable Foundation (Stan Perron Charitable Trust; to N.G. Gottardo) and American Lebanese Syrian Associated Charities (ALSAC; to A. Gajjar). Publisher Copyright: c2023 The Authors; Published by the American Association for Cancer Research.

PY - 2023/12/15

Y1 - 2023/12/15

N2 - Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression-free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4 Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients (n ¼ 3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.

AB - Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression-free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4 Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients (n ¼ 3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.

UR - http://www.scopus.com/inward/record.url?scp=85180013417&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-2331

DO - 10.1158/1078-0432.CCR-23-2331

M3 - Comment/debate

C2 - 37823794

AN - SCOPUS:85180013417

SN - 1078-0432

VL - 29

SP - 4996

EP - 4998

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 24

ER -

Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this